Sustainability at Biocon

Generics Forward integrating to Generic Formulations Generic Formulations Business - Overview Growth Drivers across Strategic Priorities Leveraging in-house API expertise to forward integrate and move up the value chain Portfolio across therapeutic segments - CVS, Metabolics, Oncology, Immunology & Auto-immune indications Development pipeline includes oral solids (potent & non-potent), topical, parenteral & device dependent products Product Pipeline Regional Expansion Expanding portfolio through Vertical integration & an in-licensing strategy Manufacturing Expansion Biocon 1 Adding capabilities - injectable facility in Bengaluru • Expanding beyond the US, either direct or through partners - Launched in EU, MoW - Direct Presence currently in select European markets & UAE Partnerships in place in Southeast Asia, Mexico, Brazil and MENA Commercialised in the US; now expanding to select European and MoW markets; directly & through partnerships Kil-$335b Global Generics Drugs Market Size 2021* *Source: Research & Markets' Report on 'Global Generic Drugs Market Report 2021', March 2021 -CTH 188 [ 10 Commercial US Formulations 6 Approved/ tentatively approved ANDAS 11

View entire presentation